Statin-induced rhabdomyolysis is a rare but potentially life-threatening condition, especially in patients with chronic kidney disease (CKD). This case report describes a 45-year-old male with CKD stage 5 who developed severe muscle pain, weakness, and dark urine after six months of atorvastatin therapy for dyslipidemia. Laboratory findings revealed markedly elevated creatine kinase (CK) levels, myoglobinemia, and myoglobinuria. Atorvastatin was immediately discontinued, and the patient received aggressive intravenous hydration. His symptoms and CK levels gradually improved without acute kidney injury. This case underscores the importance of vigilance in prescribing statins to CKD patients and highlights the need for prompt recognition and management of rhabdomyolysis. Clinicians should prioritize alternative lipid-lowering strategies for high-risk patients.